Bajaj Healthcare is trading at RS. 637.45, marking an increase of 75.55 points or 13.45% from its previous close of RS. 561.90 on the BSE.

The stock opened at RS. 572.85 and reached an intraday high of RS. 655.00, with a low of RS. 572.85. A total of 1,58,615 shares have been exchanged on the counter so far.

A BSE group 'B' stock with a face value of RS. 5, it recorded a 52-week high of RS. 655.00 on 17-Jan-2025 and a 52-week low of RS. 265.00 on 04-Jun-2024. Over the last week, the stock’s high and low stood at RS. 655.00 and RS. 499.40, respectively. The company’s current market capitalization is RS. 2,008.69 crore.

Promoters hold 59.19% of the company’s shares, while institutions own 3.04%, and non-institutional investors hold 37.78%.

In a major development, Bajaj Healthcare has secured exclusive rights from Threotech LLC to manufacture, distribute, and sell the finished formulation of Magnesium L Threonate (Magtein) in India. This agreement also allows the company to market and co-market the product in the Indian market.

The company has already been supplying the API for Magnesium L Threonate (Magtein) to the patent holder in the United States as part of an exclusive arrangement. The brand Magtein, owned by Threotech LLC, has an estimated sales value of $438 million in the U.S.

Bajaj Healthcare specializes in the development, manufacturing, and supply of Amino Acids, Nutritional Supplements, and Active Pharmaceutical Ingredients (APIs) for the Pharmaceutical, Nutraceutical, and Food industries.